Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
6.64% $5.46
America/New_York / 27 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 3 679.78 mill |
EPS: | -1.150 |
P/E: | -4.75 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 673.95 mill |
Avg Daily Volume: | 3.99 mill |
RATING 2024-03-27 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Sell | |
DE: | Strong Sell | |
P/E: | Strong Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.75 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.81x |
Company: PE -4.75 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-1.261 (-123.10%) $-6.72 |
Date: 2024-03-28 |
Expected Trading Range (DAY) |
---|
$ 4.97 - 5.95 ( +/- 8.97%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-22 | Simon Barry J. | Buy | 159 146 | Stock Option (right to buy) |
2024-02-22 | Simon Barry J. | Buy | 45 731 | Restricted Stock Units |
2024-02-22 | Lauer Regan J | Buy | 42 439 | Stock Option (right to buy) |
2024-02-22 | Lauer Regan J | Buy | 12 195 | Restricted Stock Units |
2024-02-22 | Sachs David C. | Buy | 424 390 | Stock Option (right to buy) |
INSIDER POWER |
---|
99.25 |
Last 97 transactions |
Buy: 228 380 025 | Sell: 921 083 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $5.46 (6.64% ) |
Volume | 5.12 mill |
Avg. Vol. | 3.99 mill |
% of Avg. Vol | 128.36 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.27 | N/A | Active |
---|
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Date | Signal | @ |
---|---|---|
GOGL.OL | Mar 27 - 08:09 | NOK136.70 |
EQNR.OL | Mar 27 - 08:08 | NOK286.40 |
MULTI.OL | Mar 27 - 08:05 | NOK148.00 |
DNB.OL | Mar 27 - 08:05 | NOK215.10 |
MOWI.OL | Mar 27 - 08:08 | NOK198.95 |
CADLR.OL | Mar 27 - 08:05 | NOK53.10 |
CLUSD | Mar 28 - 04:46 | $81.67 |
NOD.OL | Mar 27 - 08:05 | NOK85.80 |
SOON.OL | Mar 27 - 08:05 | NOK67.00 |
ELO.OL | Mar 27 - 08:05 | NOK34.00 |